Log in
Log in
E-mail
Password

Show password
Remember
Forgot password ?
Become a member for free
Sign up
Become a member for free
Sign up
New member
Sign up for FREE
New customer
Discover our services
  1. Homepage
  2. Equities
  3. Canada
  4. Bourse de Toronto
  5. Indiva Limited
  6. Summary
    NDVA   CA45580J1012

INDIVA LIMITED

(NDVA)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Bourse De Toronto
05/18/2022 05/19/2022 05/20/2022 05/24/2022 05/25/2022 Date
0.25(c) 0.235(c) 0.23(c) 0.21(c) 0.215 Last
96 557 85 007 79 981 147 738 29 000 Volume
0.00% -6.00% -2.13% -8.70% +2.38% Change
More quotes
Estimated financial data (e)
Sales 2022 45,7 M 35,6 M 35,6 M
Net income 2022 -24,4 M -19,0 M -19,0 M
Net Debt 2022 23,2 M 18,1 M 18,1 M
P/E ratio 2022 -5,25x
Yield 2022 -
Sales 2023 68,3 M 53,2 M 53,2 M
Net income 2023 -14,0 M -10,9 M -10,9 M
Net Debt 2023 17,4 M 13,6 M 13,6 M
P/E ratio 2023 -4,67x
Yield 2023 -
Capitalization 30,7 M 23,9 M 23,9 M
EV / Sales 2022 1,18x
EV / Sales 2023 0,70x
Nbr of Employees -
Free-Float 71,9%
More Financials
Company
Indiva Limited is a Canada-based company, which is engaged in the production, processing, and sale of cannabis and cannabis-related products. The Company creates premium cannabis capsules, whole flower, pre-rolls, and provides production and manufacturing services to peer entities. The Company produces, distributes, and markets Indiva, Artisan Batch, Bhang Chocolate, Gron Pearls & Pips, Wana Sour Gummies, Jewels... 
Read more
Sector
Pharmaceuticals
Calendar
06/23 | 04:00pmShareholder meeting
More about the company
Ratings of Indiva Limited
Trading Rating :  -
Investor Rating : 
ESG Refinitiv : 
-
More Ratings
All news about INDIVA LIMITED
05/19Indiva Q1 Loss $0.02 Per Share Vs Loss $0.03 Year Ago; Net Revenue Increases 44%; Provi..
MT
05/19TRANSCRIPT : Indiva Limited, Q1 2022 Earnings Call, May 19, 2022
CI
05/19Indiva Limited Provides Revenue Guidance for the Second Quarter of 2022
CI
05/18Indiva Limited Reports Earnings Results for the First Quarter Ended March 31, 2022
CI
05/02TRANSCRIPT : Indiva Limited - Analyst/Investor Day
CI
04/26TRANSCRIPT : Indiva Limited, Q4 2021 Earnings Call, Apr 26, 2022
CI
04/26Indiva Limited Reports Earnings Results for the Full Year Ended December 31, 2021
CI
04/26Indiva Limited Provides Net Revenue Guidance for the First Quarter of 2022
CI
04/26Indiva reports record fourth quarter and fiscal year 2021 results
AQ
04/26Indiva Limited Auditor Raises 'Going Concern' Doubt
CI
04/19Indiva to Manufacture and Distribute Dime Industry Cannabis Vaping Products in Canada
MT
04/19Indiva signs exclusive licensing and manufacturing agreement with dime industries
PR
04/19Indiva Signs Exclusive Licensing and Manufacturing Agreement with Dime Industries
CI
04/18INDIVA LIMITED(TSXV : NDVA) dropped from S&P/TSX Venture Composite Index
CI
04/13Canntab Engages Hamish Sutherland as Strategic Advisor
PR
More news
News in other languages on INDIVA LIMITED
05/19Indiva enregistre une perte de 0,02 $ par action au premier trimestre, contre une perte..
05/19Indiva Limited fournit des prévisions de revenus pour le deuxième trimestre de 2022
05/18Indiva Limited annonce ses résultats pour le premier trimestre clos le 31 mars 2022
04/26Indiva Limited annonce ses résultats pour l'exercice complet clos le 31 décembre 2021
04/26Indiva Limited fournit des prévisions de revenus nets pour le premier trimestre de 2022
More news
Analyst Recommendations on INDIVA LIMITED
More recommendations
Chart INDIVA LIMITED
Duration : Period :
Indiva Limited Technical Analysis Chart | NDVA | CA45580J1012 | MarketScreener
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 2
Last Close Price 0,21 CAD
Average target price 0,55 CAD
Spread / Average Target 162%
EPS Revisions
Managers and Directors
Carmine Edward Marotta President, Chief Executive Officer & Director
Jennifer Ann Welsh Chief Financial Officer
Robert William Carse Chief Operating Officer
Andre Lafleche Independent Director
James Yersh Independent Director
Sector and Competitors
1st jan.Capi. (M$)
INDIVA LIMITED-40.85%24
SHIJIAZHUANG YILING PHARMACEUTICAL CO., LTD.13.57%5 507
DONG-E-E-JIAO CO.,LTD.-36.57%2 942
TASLY PHARMACEUTICAL GROUP CO., LTD-34.70%2 290
PT INDUSTRI JAMU DAN FARMASI SIDO MUNCUL TBK10.98%1 935
CANOPY GROWTH CORPORATION-45.11%1 879